KRAS and hepatocellular carcinoma: For example, miR-217 is suppressed and functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS [19], and it is down-regulated and associated with poor survival in clear cell renal cell carcinoma [20], whereas it is up-regulated and involved in the pathology of hepatocellular carcinoma [21].